Sanofi, Regeneron chase 4th Dupixent approval with rare esophageal disease data

Sanofi and Regeneron's immunology superstar Dupixent is well on its way to world domination with a flood of new indications in the pipeline. To support one of those, a rare esophageal disease, the partners released new data backing up Dupixent's case for a fourth FDA approval.